Suppr超能文献

相似文献

1
Structural characterization of monoclonal antibodies targeting C-terminal Ser region of phosphorylated tau protein.
MAbs. 2019 Apr;11(3):477-488. doi: 10.1080/19420862.2019.1574530. Epub 2019 Feb 26.
3
Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.
Proteins. 2016 Apr;84(4):427-34. doi: 10.1002/prot.24988. Epub 2016 Feb 5.
4
Monoclonal antibody PHF-9 recognizes phosphorylated serine 404 of tau protein and labels paired helical filaments.
J Neurosci Res. 1996 Oct 1;46(1):90-7. doi: 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G.
5
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.
J Biol Chem. 2013 Nov 15;288(46):33081-95. doi: 10.1074/jbc.M113.494922. Epub 2013 Oct 2.
6
A Phosphorylation-Induced Turn Defines the Alzheimer's Disease AT8 Antibody Epitope on the Tau Protein.
Angew Chem Int Ed Engl. 2015 Jun 1;54(23):6819-23. doi: 10.1002/anie.201501898. Epub 2015 Apr 16.
8
Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody.
Structure. 2018 Dec 4;26(12):1626-1634.e4. doi: 10.1016/j.str.2018.08.012. Epub 2018 Oct 11.

引用本文的文献

1
Unveiling the structural mechanisms behind high affinity and selectivity in phosphorylated epitope-specific rabbit antibodies.
J Biol Chem. 2024 Dec;300(12):107989. doi: 10.1016/j.jbc.2024.107989. Epub 2024 Nov 13.
2
Neuronal hypofunction and network dysfunction in a mouse model at an early stage of tauopathy.
Alzheimers Dement. 2024 Nov;20(11):7954-7970. doi: 10.1002/alz.14273. Epub 2024 Oct 5.
3
Insights into the Structural Conformations of the Tau Protein in Different Aggregation Status.
Molecules. 2023 Jun 4;28(11):4544. doi: 10.3390/molecules28114544.
4
High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples.
Antib Ther. 2021 Feb 15;4(1):34-44. doi: 10.1093/abt/tbab004. eCollection 2021 Jan.
6
Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery.
Pharmaceuticals (Basel). 2020 Nov 16;13(11):394. doi: 10.3390/ph13110394.
7
Tau immunotherapies: Lessons learned, current status and future considerations.
Neuropharmacology. 2020 Sep 15;175:108104. doi: 10.1016/j.neuropharm.2020.108104. Epub 2020 Apr 28.
8
Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy.
EBioMedicine. 2019 Apr;42:157-173. doi: 10.1016/j.ebiom.2019.03.033. Epub 2019 Mar 22.

本文引用的文献

1
Tau-targeting therapies for Alzheimer disease.
Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z.
3
Tau filaments in neurodegenerative diseases.
FEBS Lett. 2018 Jul;592(14):2383-2391. doi: 10.1002/1873-3468.13108. Epub 2018 Jul 6.
5
Tau Kinetics in Neurons and the Human Central Nervous System.
Neuron. 2018 Mar 21;97(6):1284-1298.e7. doi: 10.1016/j.neuron.2018.02.015.
7
Cryo-EM structures of tau filaments from Alzheimer's disease.
Nature. 2017 Jul 13;547(7662):185-190. doi: 10.1038/nature23002. Epub 2017 Jul 5.
8
Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.
Am J Pathol. 2017 Jun;187(6):1399-1412. doi: 10.1016/j.ajpath.2017.01.022. Epub 2017 Apr 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验